<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32729234</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>UCHL1 from serum and CSF is a candidate biomarker for amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1420</StartPage><EndPage>1428</EndPage><MedlinePgn>1420-1428</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51141</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To identify potential ALS biomarkers in patients and to evaluate their diagnostic performance using cerebrospinal fluid (CSF) and serum.</AbstractText><AbstractText Label="METHOD">We recruited a discovery cohort, comprising 20 ALS patients and 20 controls to screen for potential CSF biomarker, UCHL1, using a Luminex neurodegenerative disease panel. To validate UCHL1's diagnostic performance, we used receiver operating characteristic (ROC) curves to determine the potential for early diagnosis in another cohort comprising 23 CSF and 69 serum ALS samples. Finally, we analyzed its correlation with clinical features.</AbstractText><AbstractText Label="RESULTS">We found significantly elevated levels of CSF-derived UCHL1 in both discovery and validation cohorts (P&#xa0;&lt;&#xa0;0.05). ROC curves revealed an AUC of 0.8288, with a sensitivity and specificity of 73.91% and 81.25%, respectively, when the cut-off value for UCHL1 was &gt;291.9&#xa0;pg/mL. A similar result was observed in the serum cohort, with the ALS group exhibiting significantly higher serum UCHL1 levels than the controls (P&#xa0;&lt;&#xa0;0.05). AUC of the ROC in the serum UCHL1 cohort was 0.7709, with sensitivity and specificity of 61.43% and 79.59%, respectively, when the cut-off value of serum UCHL1 was &gt;15.22&#xa0;pg/mL. At the early stage CSF and serum UCHL1 were significantly different between ALS patients and controls (P&#xa0;&lt;&#xa0;0.05). Furthermore, serum UCHL1 levels showed a positive relationship with the burden of UMN and LMN dysfunction, albeit with no statistical significance.</AbstractText><AbstractText Label="INTERPRETATION">Taken together, our findings suggest that ALS patients exhibit significantly elevated CSF- and serum-derived UCHL1. Moreover, our data warrant that UCHL1 displays good diagnostic performance and provide novel options for ALS early diagnosis. However, its prognostic value needs to be further investigated.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ruibing</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, the First Medical Centre, Chinese PLA General Hospital, Beijing, 100853, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jianan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, the First Medical Centre, Chinese PLA General Hospital, Beijing, 100853, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, the First Medical Centre, Chinese PLA General Hospital, Beijing, 100853, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jiayu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, the First Medical Centre, Chinese PLA General Hospital, Beijing, 100853, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chengbin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8333-7933</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine, the First Medical Centre, Chinese PLA General Hospital, Beijing, 100853, P.R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C482860">UCHL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.19.12</RegistryNumber><NameOfSubstance UI="D043222">Ubiquitin Thiolesterase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043222" MajorTopicYN="N">Ubiquitin Thiolesterase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>All authors read and approved the final manuscript. They declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32729234</ArticleId><ArticleId IdType="pmc">PMC7448153</ArticleId><ArticleId IdType="doi">10.1002/acn3.51141</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med 2017;377(2):162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001;344(22):1688&#x2013;1700.</Citation><ArticleIdList><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Liu T, Liu L, et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta&#x2010;analysis. J Neurol 2020;267(4):944&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pubmed">31797084</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, et al. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci 2019;13:1310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder DW, Kurland LT, Offord KP, et al. Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology 1986;36(4):511&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">3960325</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan K. Familial amyotrophic lateral sclerosis. Neurol Clin 2015;33(4):807&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4670044</ArticleId><ArticleId IdType="pubmed">26515623</ArticleId></ArticleIdList></Reference><Reference><Citation>Al&#x2010;Chalabi A, Hardiman O, Kiernan MC, et al. amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol 2016;15(11):1182&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu&#x2010;Rumeileh S, Steinacker P, Polischi B, et al. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimers Res Ther 2019;12(1):2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6937795</ArticleId><ArticleId IdType="pubmed">31892365</ArticleId></ArticleIdList></Reference><Reference><Citation>Agah E, Saleh F, Sanjari MH, et al. CSF and blood biomarkers in amyotrophic lateral sclerosis: protocol for a systematic review and meta&#x2010;analysis. Syst Rev 2018;7(1):237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6300914</ArticleId><ArticleId IdType="pubmed">30572951</ArticleId></ArticleIdList></Reference><Reference><Citation>Heywood WE, Galimberti D, Bliss E, et al. Identification of novel csf biomarkers for neurodegeneration and their validation by a high&#x2010;throughput multiplexed targeted proteomic assay. Mol Neurodegener 2015;10:64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4666172</ArticleId><ArticleId IdType="pubmed">26627638</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano A, Donno C, Giannetti S, et al. The astrocytic S100B protein with its receptor RAGE is aberrantly expressed in SOD1(G93A) models, and its inhibition decreases the expression of proinflammatory genes. Mediators Inflamm 2017;2017:1626204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5496121</ArticleId><ArticleId IdType="pubmed">28713206</ArticleId></ArticleIdList></Reference><Reference><Citation>Min B, Chung KC. New insight into transglutaminase 2 and link to neurodegenerative diseases. Bmb Rep 2018;51(1):5&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5796628</ArticleId><ArticleId IdType="pubmed">29187283</ArticleId></ArticleIdList></Reference><Reference><Citation>Kline RA, Kaifer KA, Osman EY, et al. Comparison of independent screens on differentially vulnerable motor neurons reveals alpha&#x2010;synuclein as a common modifier in motor neuron diseases. PLoS Genet 2017;13(3):e1006680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5391970</ArticleId><ArticleId IdType="pubmed">28362802</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu S, Wuolikainen A, Wu J, et al. Targeted multiple reaction monitoring analysis of CSF identifies UCHL1 and GPNMB as candidate biomarkers for ALS. J Mol Neurosci 2019;69(4):643&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6858390</ArticleId><ArticleId IdType="pubmed">31721001</ArticleId></ArticleIdList></Reference><Reference><Citation>Riboldi G, Nizzardo M, Simone C, et al. ALS genetic modifiers that increase survival of SOD1 mice and are suitable for therapeutic development. Prog Neurogibol 2011;95(2):133&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">21816207</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P, Weydt P, Thal DR, et al. Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathol 2020;139(1):119&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">31701227</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson KD, Lee KM, Deshpande S, et al. The neuron&#x2010;specific protein PGP 9.5 is a ubiquitin carboxyl&#x2010;terminal hydrolase. Science 1989;246(4930):670&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">2530630</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilguvar K, Tyagi NK, Ozkara C, et al. Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early&#x2010;onset progressive neurodegeneration. Proc Natl Acad Sci USA 2013;110(9):3489&#x2013;3494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3587195</ArticleId><ArticleId IdType="pubmed">23359680</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydning SL, Backe PH, Sousa M, et al. Novel UCHL1 mutations reveal new insights into ubiquitin processing. Hum Mol Genet 2017;26(6):1031&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pubmed">28007905</ArticleId></ArticleIdList></Reference><Reference><Citation>Maraganore DM, Farrer MJ, Hardy JA, et al. Case&#x2010;control study of the ubiquitin carboxy&#x2010;terminal hydrolase L1 gene in Parkinson's disease. Neurology 1999;53(8):1858&#x2013;1860.</Citation><ArticleIdList><ArticleId IdType="pubmed">10563640</ArticleId></ArticleIdList></Reference><Reference><Citation>Das BA, Patil SJ, Deshpande DV, et al. Novel splice&#x2010;site variant of UCHL1 in an indian family with autosomal recessive spastic paraplegia&#x2010;79. J Hum Genet 2018;63(8):927&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pubmed">29735986</ArticleId></ArticleIdList></Reference><Reference><Citation>Butterfield DA, Gnjec A, Poon HF, et al. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J Alzheimers Dis 2006;10(4):391&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">17183150</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998;395(6701):451&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">9774100</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng A, Tan YJ, Lu Z, et al. Plasma ubiquitin C&#x2010;terminal hydrolase L1 levels reflect disease stage and motor severity in Parkinson's disease. AGING (ALBANY NY) 2020;12(2):1488&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7053593</ArticleId><ArticleId IdType="pubmed">31932518</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondello S, Constantinescu R, Zetterberg H, et al. CSF alpha&#x2010;synuclein and UCH&#x2010;L1 levels in Parkinson's disease and atypical Parkinsonian disorders. Parkinsonism Relat Disord 2014;20(4):382&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">24507721</ArticleId></ArticleIdList></Reference><Reference><Citation>Recabarren&#x2010;Leiva D, Alarcon M. New insights into the gene expression associated to amyotrophic lateral sclerosis. Life Sci 2018;193:110&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">29241710</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel R, Brophy C, Hickling M, et al. Alternative cleavage and polyadenylation of genes associated with protein turnover and mitochondrial function are deregulated in Parkinson's, Alzheimer's and ALS disease. BMC Med Genomics 2019;12(1):60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6507032</ArticleId><ArticleId IdType="pubmed">31072331</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham SH, Liu H. Life and death in the trash heap: the ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral ischemia. Ageing Res Rev 2017;34:30&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5250550</ArticleId><ArticleId IdType="pubmed">27702698</ArticleId></ArticleIdList></Reference><Reference><Citation>Genc B, Jara JH, Schultz MC, et al. Absence of UCHL1 function leads to selective motor neuropathy. Ann Clin Transl Neurol 2016;3(5):331&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4863746</ArticleId><ArticleId IdType="pubmed">27231703</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridel C, van Wieringen WN, Zetterberg H, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta&#x2010;analysis. Jama Neurol 2019;76(9):1035&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6580449</ArticleId><ArticleId IdType="pubmed">31206160</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop P, Rocca D, Henley JM. Ubiquitin C&#x2010;terminal hydrolase L1 (UCH&#x2010;L1): structure, distribution and roles in brain function and dysfunction. Biochem J 2016;473(16):2453&#x2013;2462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4980807</ArticleId><ArticleId IdType="pubmed">27515257</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>